[Featured Stock] HK Innoen Soars on Success News of US COVID-19 Treatment

[Asia Economy Reporter Ji Yeon-jin] HK Innoen is showing strength as it is grouped as a related stock following the news of the successful development of a COVID-19 treatment by the U.S. pharmaceutical company Merck (MSD) on the 5th.

As of 10:40 AM on the 5th, HK Innoen is trading at 63,600 won, up 21.14% (11,100 won) compared to the previous trading day.

HK Innoen signed a joint sales and distribution agreement with Merck in January for seven types of vaccines.

On the 1st (local time), Merck announced clinical results showing that its oral COVID-19 treatment under development, Molnupiravir, reduces hospitalization and mortality rates among COVID-19 patients.